Next Article in Journal
TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis
Next Article in Special Issue
Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
Previous Article in Journal
The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
Previous Article in Special Issue
What Can Machine Learning Approaches in Genomics Tell Us about the Molecular Basis of Amyotrophic Lateral Sclerosis?
 
 
Review

Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back

1
Genethon, 91000 Evry, France
2
Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(4), 258; https://doi.org/10.3390/jpm10040258
Received: 31 October 2020 / Revised: 20 November 2020 / Accepted: 23 November 2020 / Published: 28 November 2020
Neuromuscular disorders are a large group of rare pathologies characterised by skeletal muscle atrophy and weakness, with the common involvement of respiratory and/or cardiac muscles. These diseases lead to life-long motor deficiencies and specific organ failures, and are, in their worst-case scenarios, life threatening. Amongst other causes, they can be genetically inherited through mutations in more than 500 different genes. In the last 20 years, specific pharmacological treatments have been approved for human usage. However, these “à-la-carte” therapies cover only a very small portion of the clinical needs and are often partially efficient in alleviating the symptoms of the disease, even less so in curing it. Recombinant adeno-associated virus vector-mediated gene transfer is a more general strategy that could be adapted for a large majority of these diseases and has proved very efficient in rescuing the symptoms in many neuropathological animal models. On this solid ground, several clinical trials are currently being conducted with the whole-body delivery of the therapeutic vectors. This review recapitulates the state-of-the-art tools for neuron and muscle-targeted gene therapy, and summarises the main findings of the spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy (XLMTM) trials. Despite promising efficacy results, serious adverse events of various severities were observed in these trials. Possible leads for second-generation products are also discussed. View Full-Text
Keywords: AAV; genetic neuromuscular disorders; gene therapy; clinical trials; toxicity; SMA; DMD; XLMTM AAV; genetic neuromuscular disorders; gene therapy; clinical trials; toxicity; SMA; DMD; XLMTM
Show Figures

Figure 1

MDPI and ACS Style

Buscara, L.; Gross, D.-A.; Daniele, N. Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back. J. Pers. Med. 2020, 10, 258. https://doi.org/10.3390/jpm10040258

AMA Style

Buscara L, Gross D-A, Daniele N. Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back. Journal of Personalized Medicine. 2020; 10(4):258. https://doi.org/10.3390/jpm10040258

Chicago/Turabian Style

Buscara, Laurine, David-Alexandre Gross, and Nathalie Daniele. 2020. "Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back" Journal of Personalized Medicine 10, no. 4: 258. https://doi.org/10.3390/jpm10040258

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop